Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

First Posted Date
2007-06-05
Last Posted Date
2024-11-08
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Target Recruit Count
150
Registration Number
NCT00482261
Locations
🇦🇺

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Anticoagulant Therapy During Pacemaker Implantation

First Posted Date
2007-05-28
Last Posted Date
2012-09-17
Lead Sponsor
University of Turku
Target Recruit Count
447
Registration Number
NCT00479362
Locations
🇫🇮

Turku University Hospital, Turku, Finland

Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus

First Posted Date
2007-05-17
Last Posted Date
2014-07-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
122
Registration Number
NCT00474903
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2007-05-07
Last Posted Date
2010-11-15
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
144
Registration Number
NCT00470561
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer

First Posted Date
2007-05-03
Last Posted Date
2017-05-31
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
79
Registration Number
NCT00468910
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

The Effect of Serum LDL Lowering on Aspirin Resistance

Not Applicable
Completed
Conditions
First Posted Date
2007-04-27
Last Posted Date
2013-02-20
Lead Sponsor
Ziv Hospital
Target Recruit Count
40
Registration Number
NCT00466154
Locations
🇮🇱

Internal Medicine Department A ,Ziv Goverment Hospital, Safed, Israel

The Indian POLYCAP Study (TIPS)

First Posted Date
2007-03-06
Last Posted Date
2010-09-23
Lead Sponsor
St. John's Research Institute
Target Recruit Count
2050
Registration Number
NCT00443794
Locations
🇮🇳

MGM, Indore, Madhya Pradesh, India

🇮🇳

Sri Ganga Ram Hospital, New Delhi, Delhi, India

🇮🇳

Fortis Hospital, Noida, Delhi, India

and more 50 locations

A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin

Phase 1
Completed
Conditions
First Posted Date
2007-03-01
Last Posted Date
2009-01-12
Lead Sponsor
POZEN
Target Recruit Count
80
Registration Number
NCT00441519
Locations
🇺🇸

POZEN, Chapel Hill, North Carolina, United States

🇨🇦

MDS Pharma Services, Montreal, Quebec, Canada

To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin

Phase 1
Completed
Conditions
First Posted Date
2007-03-01
Last Posted Date
2007-03-01
Lead Sponsor
POZEN
Target Recruit Count
80
Registration Number
NCT00442052
Locations
🇨🇦

MDS Pharma Services, Montreal, Quebec, Canada

🇺🇸

POZEN, Chapel Hill, North Carolina, United States

Aspirin and Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients

First Posted Date
2007-01-29
Last Posted Date
2007-01-29
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
20
Registration Number
NCT00427271
Locations
🇧🇷

Hospital de Clínicas de Porto Aelgre, Porto Alegre, RS, Brazil

© Copyright 2024. All Rights Reserved by MedPath